European Union - English - EMA (European Medicines Agency)

actavis group ptc ehf - reteplase - myocardial infarction - antithrombotic agents - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

beijing tong ren tang australia pty ltd - panax ginseng, quantity: 4 mg; glycyrrhiza glabra, quantity: 1 mg; rehmannia glutinosa, quantity: 16 mg; angelica polymorpha, quantity: 4.5 mg; paeonia lactiflora, quantity: 4 mg; salvia miltiorrhiza, quantity: 4 mg; ligusticum striatum, quantity: 2 mg; astragalus membranaceus, quantity: 1 mg; cyperus rotundus, quantity: 4 mg; asparagus cochinchinensis, quantity: 2 mg; dioscorea oppositifolia, quantity: 4 mg; stellaria dichotoma, quantity: 800 microgram; black boned chicken powder, quantity: 28.5 mg - pill - excipient ingredients: purified honey - traditionally used in chinese medicine to relieve weariness/tiredness/fatigue/feeling of weakness ; traditionally used in chinese medicine to decrease/reduce/relieve symptoms of menstruation (linked indication:relieves mid-cycle menstrual pain; decrease/reduce/relieve menstrual cycle irregularity/irregular periods; decrease/reduce heavy menstruation/periods)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - reteplase -

European Union - English - EMA (European Medicines Agency)

ucb pharma sa - lacosamide - epilepsy - antiepileptics, - vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamide - epilepsy - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.•         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

European Union - English - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamide - epilepsy - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

European Union - English - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsy - antiepileptics, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Singapore - English - HSA (Health Sciences Authority)

flowe & earth brand - pill

Australia - English - Department of Health (Therapeutic Goods Administration)

epilepsy edge australia pty ltd - 36693 - alarm, epilepsy - the p154 models cover a range of small monitors that detect abnormal conditions occurring in a bed that might indicate an epilepsy episode. these cover bed movement, bed wetting, sounds and bed vacation. the alarms are transmitted by safelink radio or to a connected nurse call or telecare system

European Union - English - EMA (European Medicines Agency)

biocodex - stiripentol - myoclonic epilepsy, juvenile - antiepileptics, - diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (smei, dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.